key: cord-0049822-bjnewlyg
authors: Lazzerini, Pietro Enea; Laghi-Pasini, Franco; Acampa, Maurizio; Boutjdir, Mohamed; Leopoldo Capecchi, Pier
title: IL-6 (Interleukin 6) Blockade and Heart Rate Corrected QT Interval Prolongation in COVID-19
date: 2020-07-23
journal: Circ Arrhythm Electrophysiol
DOI: 10.1161/circep.120.008791
sha: b41d18333a7e37006c9156288bb255e342bc3b56
doc_id: 49822
cord_uid: bjnewlyg

nan

T he recently published Multi-Society Document from American Heart Association/American College of Cardiology/Heart Rhythm Society by Roden et al 1 conveys an important alert on heart rate corrected QT interval (QTc) prolongation and Torsades-de-pointes risk associated with exploratory coronavirus disease 2019 (COVID-19) treatments. Indeed, accumulating evidence indicates that COVID-19 patients are burdened by a higher risk of malignant ventricular arrhythmias, with a potential contributing role of repurposed antiviral therapies. 1, 2 In particular, the authors underlined as among the exploratory COVID-19 treatments are included antimalarials (chloroquine and hydroxychloroquine), protease inhibitors (lopinavir/ritonavir), and azithromycin, 1 all drugs listed as definite or possible causes of Torsades-de-pointes at https://www.crediblemeds.org.

In this view, recommendations about electrocardiographic/QTc monitoring along with a decisional guide for optimizing risk/benefit ratio when exploratory drugs are administered is of crucial importance. 1 Moreover, the document also highlights as severely ill patients with COVID-19 are frequently burdened by comorbidities, specifically electrolyte imbalances, concomitant QT-prolonging drugs, and the high-grade systemic inflammatory state, 1-3 further increasing Torsades-de-pointes susceptibility. 1 However, while correcting hypokalemia and hypomagnesemia is recommended, the possibility of targeting inflammation to reduce arrhythmia risk has not been addressed, although supported by several data: (1) cytokine levels, particularly IL-6 (interleukin 6), are markedly elevated in severe COVID-19, where the anti-IL-6 receptor monoclonal-antibody tocilizumab seems to be able to reduce mortality 2 ; (2) it has been demonstrated that IL-6 directly blocks the human-ether-a-go-go-related potassium channel 2 and that high circulating IL-6 levels (≥10 pg/mL) due to different inflammatory diseases associate with QTc prolongation and Torsades-de-pointes development 3 ; (3) IL-6 can also potently inhibit cytochrome p450-3A potentially increasing bioavailability of several QT-prolonging drugs (macrolides, azole antifungals, antidepressants, and antihistamines), as well as induce central hypothalamus-mediated cardiac sympathetic system hyperactivation, a well-recognized trigger for life-threatening arrhythmic events in patients with long-QT syndrome 2 ; (4) in active rheumatoid arthritis, tocilizumab rapidly reversed QTc prolongation by controlling systemic inflammation. 4 A recent study performed on a large cohort of hospitalized patients in the New York City area supports the inherent relevance of these mechanisms in COVID-19. In fact, at admission, that is, before treatment with exploratory antiviral drugs, a high percentage of patients who underwent ECG showed marked QTc prolongation, >500 ms (6.1%, 260/4250), along with elevated C-reactive protein levels (median 13.0 mg/dL). 5 As a complement to the Multi-Society Document, 1 we propose the perspective to consider administration of anti-IL-6 targeted drugs (tocilizumab and sarilumab) in COVID-19, not only in patients with signs of multi-organ dysfunction, but also in those with QTc>500 ms, particularly when IL-6≥10 pg/mL (Figure) . In these subjects, by specifically dampening inflammation-driven arrhythmic risk, IL-6 blockade could reduce the need of withholding/withdrawing potentially useful COVID-19 repurposed pharmacotherapies. Although it is not currently known how to select patients in whom correction of QTc prolongation will improve overall outcome, nevertheless evidence indicates that a short-term anti-IL-6 treatment is safe, also potentially decreasing the extent of myocardial injury frequently observed in COVID-19. A phase II clinical trial evaluating for the first time the impact of tocilizumab in nonrheumatoid arthritis subjects with an acute cardiac damage demonstrated how in these patients, a single administration of tocilizumab reduced the inflammatory response and myocardial injury (troponin levels), with no safety concerns (including infections) in the following 6 months follow-up period. 

Considerations for drug interactions on QTc in exploratory COVID-19 (Coronavirus Disease 2019) treatment

COVID-19, Arrhythmic risk, and inflammation: mind the gap! Circulation

Systemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes

Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: tocilizumab reduces corrected QT interval by controlling systemic inflammation

and the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

 COVID-19 coronavirus disease 2019  IL-6 interleukin 6 QTc heart rate corrected QT interval

Yellow boxes represent methods to reverse the mechanisms that related arrows point. *When all other more conventional reversible causes are addressed.